Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...

Sanofi (SNY) halts shipments of cholesterol drug Praluent developed with Regeneron (REGN) due to availability issues. Read ...

Paris: Sanofi has announced that the European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible ...

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict ...

Drugmakers Sanofi, Eli Lilly, Novo Nordisk and AstraZeneca must face a lawsuit from two health centers accusing them of ...

Sanofi has announced a new clinical study titled ‘A Multi-center, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) ...

Sanofi is conducting a Phase 3 study titled A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study, Followed by Open-label Extensions, to Evaluate the Efficacy of Oral ...

Digitization has allowed Sanofi to optimize manufacturing and automate document preparation. And now, the firm predicts that ...

In addition to IgG4-related disease, rilzabrutinib has received orphan designations for immune thrombocytopenia (ITP) in the US, the EU, and Japan; and for warm autoimmune hemolytic anemia, IgG4-RD ...

Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...